GSK’s anti-TIM-3 antibody fails in Phase III NSCLC trial
GSK is also investigating cobolimab in Phase II studies in liver cancer, cervical cancer and melanoma.
31 July 2025
31 July 2025
GSK is also investigating cobolimab in Phase II studies in liver cancer, cervical cancer and melanoma.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.